
The FDA is making GlaxoSmithKline wait for a verdict on the manufacturer’s investigational type 2 diabetes treatment albiglutide, extending its …

GlaxoSmithKline has insisted its new long-acting Type 2 diabetes drug albiglutide remains on course for filing following topline results from …
GlaxoSmithKline’s long-acting diabetes drug albiglutide has failed in a head-to-head trial against Novo Nordisk’s Victoza. Albiglutide is an injectable glucagon-like …
ESTEVE CDMO adds $17.5m to Illinois expansion
Brenntag and dsm-firmenich expand biopharma vitamin partnership

